International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 4, Issue 3 | Case Series | Open Access DOI
Subhash Saxena*
Subhash Saxena1*, Tanushree2, Anil Tambi3, Priya Mathur4, Navneet Saxena5
1Associate professor, Department of Medicine- Jaipur National University Institute for Medical Sciences and Research Centre. Jagatpura -Jaipur-Rajasthan
2Consultant psychiatrist, Vimhns, Jaipur
3Senior consultant psychiatrist, formerly senior professor SMS, Dept. of Psychiatry- SMS MC Jaipur-2.
4Critical care head ,Apex hospital, Malviya Nagar, Jaipur-2
5Professor, Department of Medicine, Jaipur National University Institute for Medical Sciences and Research Centre. Jagatpura, Jaipur, Rajasthan
*Correspondence to: Subhash Saxena
Fulltext PDFPrevention and treatment of type 2 diabetes and obesity are problematic for individuals with schizophrenia and other patients on antipsychotic therapy because atypical antipsychotics and mental distress themselves increase appetite, thus promoting subsequent body weight gain and deterioration of glycaemic control. Almost half of patients with schizophrenia have body mass index (BMI) ≥ 25- and 2.5-times higher risk of developing T2D compared to healthy individuals [1]. Antipsychotic (AP) drugs are the cornerstone treatment for schizophrenia and are commonly used for other psychiatric disorders. However, they are associated with severe metabolic adverse effects, including weight gain, dyslipidaemia, and insulin resistance [2]. Particularly, insulin resistance and type 2 diabetes mellitus (T2DM) induce Non-alcoholic fatty liver disease (NAFLD) onset, deterioration of liver inflammation/fibrosis, and development of hepatocellular carcinoma. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, accounting for approximately 25% of chronic liver disease cases worldwide [3].
Subhash Saxena, Tanushree, Anil Tambi, Priya Mathur, Navneet Saxena. Oral Semaglutide for the Treatment of Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease and Antipsychotic-Associated Weight Gain (AAWG) Not Responding to Metformin – A Case Series. Int Clinc Med Case Rep Jour. 2025;4(3):1-12.